glp-1 news nov 2025 November in review: breakthroughs, UPFs under fire, Novonesis advances healthy longevity GLP-1 Therapies May Benefit MPN

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

A head-to-head review of clinical studies determined that among available GLP-1 RAs, there were A1C reductions from 0.78% to 1.9%

Patients prescribed GLP-1 medications for diabetes or weight management have reported unexpected reductions in their desire to consume alcohol, with some describing a complete loss of interest in drinking

Depression and obesity: evidence of shared biological mechanisms

Cited 2/3/16

Do I still need to diet and exercise while taking GLP-1 medication